Global Immune Checkpoint Inhibitors Market – Industry Trends and Forecast to 2027

  • Pharmaceutical
  • Upcoming Report
  • May 2020
  • Global
  • 350 Pages
  • No of Tables: 60
  • No of Figures: 220

Global Immune Checkpoint Inhibitors Market By Type (CTLA-4 Inhibitor, PD-1 Inhibitor, PD-L1 Inhibitor), Therapeutic Application (Melanoma, Lung Cancer, Urothelial Carcinoma, Hodgkin Lymphoma, Squamous Cell Carcinoma, Blood Cancer, Others), Distribution Channel (Retail Pharmacies, Hospital Pharmacies), Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa) – Industry Trends & Forecast to 2026

Global Immune Checkpoint Inhibitors Market By Indication (Breast Cancer, Bladder Cancer, Cervical Cancer, Hodgkin Lymphoma, Liver Cancer, Lung Cancer, Kidney Cancer, Solid Cancer, Others), Target (PD-1, PD-L1, CTLA-4, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Others), Country (U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa) Industry Trends and Forecast to 2027

Immune Checkpoint Inhibitors Market

Market Analysis and Insights: Global Immune Checkpoint Inhibitors Market

Immune checkpoint inhibitors market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses the market is growing with the healthy CAGR in the above-mentioned research forecast period. Rising prevalence of cancer related disorders worldwide and emerging markets are the factors responsible for the growth of this market.

Growing cases of cancer drives the immune checkpoint inhibitors market. Due to adoption of unhealthy lifestyle and genetic modification/alteration also boost up the immune checkpoint inhibitors market growth. However, increased advancement in the treatment of cancer and rise in population with immune system diseases worldwide will boost up the global immune checkpoint inhibitors market. But, stringent FDA guidelines for the drug approval of new drug & adverse effect after the treatment may hamper the immune checkpoint inhibitors market.

Immune checkpoint inhibitors are the molecules on some immune cells that need to be activated or inactivated to start an immune response and prevent the immune system by damage. These checkpoint inhibitors used to treat cancer but they do not work directly on the tumor cells. Cancer cells sometimes find ways to use these checkpoints to avoid the attacked by immune system. But drugs that targets theses checkpoint hold lot of potential for the cancer treatment. Immune checkpoint inhibitors act against the checkpoint protein called CTLA-4, PD-1 or its partner protein PD-L1.

This immune checkpoint inhibitors market report provides details of market share, new developments and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographical expansions and technological innovations in the market. To understand the analysis and the market scenario contact us for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

Global Immune Checkpoint Inhibitors Market Scope and Market Size

Immune checkpoint inhibitors market is segmented on the basis of indication, target, route of administration, end-users and distribution channel.

  • On the basis of indication, the immune checkpoint inhibitors market is segmented into breast cancer, bladder cancer, cervical cancer, Hodgkin lymphoma, liver cancer, lung cancer, kidney cancer, solid cancer and others
  • On the basis of target, the immune checkpoint inhibitors market is segmented into PD-1, PD-L1, CTLA-4 and others
  • Route of administration segment of immune checkpoint inhibitors market is segmented into oral, parenteral and others
  • On the basis of end-users, the immune checkpoint inhibitors market is segmented into hospitals, specialty clinics and others
  • On the basis of distribution channel, the immune checkpoint inhibitors market has also been segmented into hospital pharmacy, retail pharmacy, others

Key Developments in the Market:

  • In June 2019, Merck & Co., Inc., received FDA approval for the KEYTRUDA (pembrolizumab) for two new indications. KEYTRUDA is the first-line treatment of patients with metastatic or with unresectable, recurrent head and neck squamous cell carcinoma as monotherapy for patients whose tumors express PD-L1 (CPS ≥1) or in combination with platinum and fluorouracil (FU) regardless of pd-l1 expression. With this approval, the company has enhanced its product portfolio in the market.
  • In September 2018, Regeneron Pharmaceuticals, Inc., received FDA approval for the Libtayo (cemiplimab-rwlc). Libtayo (cemiplimab-rwlc) first and only treatment for locally advanced cutaneous squamous cell carcinoma and metastatic cutaneous squamous cell carcinoma for curative surgery or curative radiation. Libtayo is a fully-human monoclonal antibody targeting the immune checkpoint receptor PD-1. With this approval, the company has enhanced the credibility of their product in the market

Immune Checkpoint Inhibitors Market Country Level Analysis

Immune checkpoint inhibitors market is analysed and market size information is provided by country, indication, target, route of administration, end-users and distribution channel as referenced above.

The countries covered in the immune checkpoint inhibitors market report are U.S., Canada, Mexico in North America, Brazil, Argentina, Peru, Rest of South America, as part of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific in Asia-Pacific, U.A.E, Egypt, Israel, Saudi Arabia, Kuwait, South Africa, Rest of Middle East and Africa, as a part of Middle East and Africa.

North America accounts the largest market share due to the presence of key manufacture of the product, high research and development and healthcare expenditure and skilled professionals. Europe is considered second largest market for immune checkpoint inhibitors due to increased cancer treatment & surgeries. Asia-Pacific is expected to account for the largest market share over coming years for the immune checkpoint inhibitors market due to increased government awareness programs and number of generic drugs.

The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Patient Epidemiology Analysis

Immune checkpoint inhibitors market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

Competitive Landscape and Immune checkpoint inhibitors Market Share Analysis

Immune checkpoint inhibitors market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to immune checkpoint inhibitors market.

The major players covered in the immune checkpoint inhibitors market are Merck & Co., Inc., Bristol -Myers Squibb Company, Regeneron Pharmaceuticals, Genetech Inc., AstraZeneca, EMD Serono, Inc., Novartis AG, and Pfizer Inc., among others. 

Customization Available: Global Immune Checkpoint Inhibitors Market

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analysed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report.


SKU-

Please fill in the below form for detailed Table of Content

Please fill in the below form for detailed List of Table

Please fill in the below form for detailed List of Figure

CHOOSE LICENCE TYPE
  • 7000.00
  • 4800.00
  • 3000.00
  • 8000.00
  • 12000.00
Why Choose Us
Unlocking New Opportunities on this Report Post Covid-19